MiniMed Group (NASDAQ:MMED) Price Target Raised to $26.00

MiniMed Group (NASDAQ:MMED) had its target price upped by Mizuho from $21.00 to $26.00 in a report published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts also recently weighed in on MMED. Piper Sandler reiterated a “neutral” rating and issued a $16.00 price target on shares of MiniMed Group in a report on Thursday, June 4th. Benchmark restated a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th. BTIG Research increased their target price on MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday. UBS Group began coverage on MiniMed Group in a research report on Tuesday, July 28th. They set a “buy” rating and a $25.00 target price for the company. Finally, Wells Fargo & Company lowered their target price on shares of MiniMed Group from $26.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, June 4th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.77.

MiniMed Group Price Performance

MiniMed Group stock opened at $23.28 on Wednesday. The stock has a market cap of $6.55 billion and a price-to-earnings ratio of -34.24. MiniMed Group has a 1-year low of $10.65 and a 1-year high of $24.43. The stock has a 50-day moving average price of $18.21.

MiniMed Group (NASDAQ:MMED) last announced its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. The business’s revenue was up 15.6% on a year-over-year basis. On average, equities analysts predict that MiniMed Group will post 0.7 EPS for the current year.

Institutional Investors Weigh In On MiniMed Group

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Parkside Financial Bank & Trust purchased a new stake in shares of MiniMed Group in the 2nd quarter worth $28,000. California State Teachers Retirement System purchased a new stake in MiniMed Group in the second quarter worth about $89,000. Legal & General Group Plc bought a new position in MiniMed Group during the 2nd quarter worth about $91,000. The Manufacturers Life Insurance Company purchased a new position in MiniMed Group during the 2nd quarter valued at about $185,000. Finally, Punch & Associates Investment Management Inc. purchased a new stake in shares of MiniMed Group in the 2nd quarter worth approximately $292,000.

More MiniMed Group News

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.